Soluble epoxide hydrolase: A potential target for metabolic diseases

Journal of Diabetes
Jinlong HeDing Ai


Epoxyeicosatrienoic acids (EETs), important lipid mediators derived from arachidonic acid, have many beneficial effects in metabolic diseases, including atherosclerosis, hypertension, cardiac hypertrophy, diabetes, non-alcoholic fatty liver disease, and kidney disease. Epoxyeicosatrienoic acids can be further hydrolyzed to less active diols by the enzyme soluble epoxide hydrolase (sEH). Increasing evidence suggests that inhibition of sEH increases levels of EETs, which have anti-inflammatory effects and can prevent the development of hypertension, atherosclerosis, heart failure, fatty liver, and multiple organ fibrosis. Arachidonic acid is the most abundant omega-6 polyunsaturated fatty acid (PUFA) and shares the same set of enzymes with omega-3 PUFAs, such as docosahexaenoic acid and eicosapentaenoic acid. The omega-3 PUFAs and metabolites, such as regioisomeric epoxyeicosatetraenoic acids and epoxydocosapentaenoic acids, have been reported to have strong vasodilatory and anti-inflammatory effects. Therefore, sEH may be a potential therapeutic target for metabolic disorders. In this review, we focus on our and other recent studies of the functions of sEH, including the effects of its eicosanoid products from both omega-3 and o...Continue Reading


Sep 26, 2000·The Journal of Biological Chemistry·C J SinalF J Gonzalez
Mar 8, 2002·Hypertension·Birgit LauterbachWolf-Hagen Schunck
Sep 12, 2006·Cardiovascular Drug Reviews·John D Imig
May 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Ding AiYi Zhu
Sep 20, 2007·Journal of Cardiovascular Pharmacology·Nipavan ChiamvimonvatBruce D Hammock
Nov 1, 2008·Journal of Molecular and Cellular Cardiology·S N BatchuJ M Seubert
Jan 8, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ding AiYi Zhu
Feb 27, 2009·Journal of Lipid Research·Matthew W BuczynskiEdward A Dennis
Aug 12, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Le-Ning ZhangYi-Xin Jim Wang
May 4, 2010·Cardiovascular Therapeutics·Hong QiuNipavan Chiamvimonvat
May 17, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ayala LuriaBruce D Hammock
Aug 13, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Ahmed A ElmarakbyJohn D Imig
Dec 16, 2011·Journal of Medicinal Chemistry·Hong C Shen, Bruce D Hammock
Jan 13, 2012·International Journal of Cardiology·Andrew R KompaHenry Krum
May 16, 2012·Proceedings of the National Academy of Sciences of the United States of America·Paul C Norris, Edward A Dennis
Jun 29, 2012·American Journal of Physiology. Endocrinology and Metabolism·Guangzhi ChenDao Wen Wang
Jul 11, 2012·BMJ : British Medical Journal·Iain J MarshallChristopher McKevitt
Oct 2, 2012·Annual Review of Pharmacology and Toxicology·Christophe Morisseau, Bruce D Hammock
Nov 16, 2012·American Journal of Physiology. Renal Physiology·Qian WangYi Zhu
Nov 28, 2012·British Journal of Pharmacology·Hassan N AlthurwiAyman O S El-Kadi
May 25, 2013·Gene·Todd R Harris, Bruce D Hammock
Jun 21, 2013·Clinica Chimica Acta; International Journal of Clinical Chemistry·Xiao-Hua YuChao-Ke Tang
Aug 1, 2013·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Sari A JouihanNabil J Alkayed
Sep 5, 2013·JAMA : the Journal of the American Medical Association·Yu XuUNKNOWN 2010 China Noncommunicable Disease Surveillance Group
Apr 3, 2014·Journal of Cardiovascular Pharmacology·Arzu UluBruce D Hammock
Aug 29, 2014·American Journal of Physiology. Renal Physiology·Jinu KimBabu J Padanilam
Jan 1, 2015·Proceedings of the National Academy of Sciences of the United States of America·Cristina López-VicarioJoan Clària

❮ Previous
Next ❯


Oct 25, 2016·Trends in Pharmacological Sciences·Mikhail RomashkoJohn A McClung
Jan 29, 2019·Frontiers in Pharmacology·Jun-Yan Liu
Apr 6, 2019·Oxidative Medicine and Cellular Longevity·Alessio MolfinoMaurizio Muscaritoli
Mar 21, 2020·International Journal of Molecular Sciences·Abdelkrim KhadirAli Tiss
Feb 23, 2019·American Journal of Physiology. Gastrointestinal and Liver Physiology·Liu YaoYi Zhu
Feb 18, 2020·Frontiers in Molecular Neuroscience·Michelle Flores DominguesCelia Regina Carlini
Mar 3, 2020·Frontiers in Physiology·K Lockhart JamiesonJohn M Seubert
Nov 2, 2019·Prostaglandins & Other Lipid Mediators·Marco RahmStefanie M Hauck
Dec 16, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jie ZhangQingsong Jiang
Apr 29, 2019·The Journal of Nutritional Biochemistry·Kamil BorkowskiGregory C Shearer
Jun 4, 2021·Drug Discovery Today·Maria BzówkaArtur Góra
Jun 12, 2021·Frontiers in Physiology·Jinjie DuanChunjiong Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds


Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

© 2021 Meta ULC. All rights reserved